Future oncology (London, England)
Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.
Eric Van Cutsem
Published: 202510.1080/14796694.2025.2567230
No abstract available for this study.